Growth Regulation of Activated T Cells by FADD

FADD 对活化 T 细胞的生长调节

基本信息

  • 批准号:
    6683606
  • 负责人:
  • 金额:
    $ 26.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-12-01 至 2007-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): During the course of an immune response, T cells are confronted with a number of stages where appropriate decisions between survival, proliferation and death are crucial. Although many of these choices are regulated by distinct signal transduction pathways, it is becoming clear that some of the molecules regulating these disparate pathways are shared in common. We have discovered a novel pathway involving FADD/Mortl, that links apoptotic control in T cells to cellular growth control. FADD is a cytoplasmic adapter molecule that physically associates with death receptors and caspase-8 and -10; this association results in caspase activation. Using mice expressing a mutant form of FADD in T cells, we have demonstrated that this apoptosis-inducing molecule is critical for normal T cell responsiveness to a number of mitogenic stimuli. We outline several approaches in this proposal to more fully understand the means by which FADD coordinates the choice between proliferation and apoptosis in T cells. In this proposal, we will first determine if FADD is required for the proliferation of T cells that have differentiated in a normal background. This will allow us to distinguish the role of FADD in the development of T cells from its potential to act as a costimulatory signaling component in mature peripheral T cells. Next, we will study the activation of known signaling pathways in the context of T cells expressing dominant negative FADD to determine how FADD participates in the institution and maintenance of proliferating CD4+ and CD8+ T cells. We will also address the potential that caspase-8 may play a role in this FADD-dependent costimulatory process by introducing dominant-negative forms of caspase-8 into primary T cells. Further, we will study the differential processing of caspase-8 to understand how this molecule might induce and maintain proliferation in a T cell response and later, potentiate activation-induced cell death. The mechanism by which FADD regulates both proliferation and apoptosis in T cells is an enigma. However, it is clear that both proliferative and apoptotic regulation of this compartment of the immune system is crucial for the avoidance of cancers, autoimmunity and pathogenesis. Therefore, results from these proposed studies will not only shed light on an important molecule linking these two processes, but will also highlight a signaling paradigm that is critical for the evasion of human disease.
描述(由申请人提供):在免疫应答过程中,T细胞面临许多阶段,在这些阶段中,存活、增殖和死亡之间的适当决定至关重要。虽然这些选择中的许多由不同的信号转导途径调节,但越来越清楚的是,调节这些不同途径的一些分子是共同的。我们已经发现了一种涉及FADD/Mort 1的新途径,其将T细胞中的凋亡控制与细胞生长控制联系起来。FADD是与死亡受体和半胱天冬酶-8和-10物理缔合的细胞质衔接分子;这种缔合导致半胱天冬酶活化。使用在T细胞中表达突变形式的FADD的小鼠,我们已经证明,这种凋亡诱导分子对于正常T细胞对许多促有丝分裂刺激的反应性是至关重要的。我们概述了几种方法,在这个建议,以更充分地了解FADD协调T细胞增殖和凋亡之间的选择的手段。在这个提议中,我们将首先确定FADD是否是在正常背景下分化的T细胞增殖所必需的。这将使我们能够区分FADD在T细胞发育中的作用与其作为成熟外周T细胞中共刺激信号成分的潜力。接下来,我们将研究在表达显性阴性FADD的T细胞的背景下已知信号通路的激活,以确定FADD如何参与增殖的CD 4+和CD 8 + T细胞的建立和维持。我们还将通过向原代T细胞中引入显性负性形式的caspase-8来解决caspase-8可能在这种FADD依赖性共刺激过程中发挥作用的潜力。此外,我们将研究caspase-8的差异处理,以了解这种分子如何诱导和维持T细胞反应中的增殖,以及后来如何增强活化诱导的细胞死亡。FADD调节T细胞增殖和凋亡的机制是一个谜。然而,很明显,免疫系统的这一区室的增殖和凋亡调节对于避免癌症、自身免疫和发病机制至关重要。因此,这些拟议研究的结果不仅将揭示连接这两个过程的重要分子,而且还将突出对人类疾病逃避至关重要的信号传导模式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Craig Michael Walsh其他文献

Craig Michael Walsh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Craig Michael Walsh', 18)}}的其他基金

Hyperion multi-parameter high-dimensional imaging mass cytometry platform
Hyperion多参数高维成像质谱流式分析平台
  • 批准号:
    10193821
  • 财政年份:
    2021
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    8093107
  • 财政年份:
    2010
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    7917835
  • 财政年份:
    2009
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    7430248
  • 财政年份:
    2007
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    7072289
  • 财政年份:
    2005
  • 资助金额:
    $ 26.21万
  • 项目类别:
GROWTH REGULATION OF ACTIVATED T CELLS BY FADD
FADD 对活化 T 细胞的生长调节
  • 批准号:
    7182391
  • 财政年份:
    2005
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    6983696
  • 财政年份:
    2005
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    7197336
  • 财政年份:
    2005
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    7570029
  • 财政年份:
    2005
  • 资助金额:
    $ 26.21万
  • 项目类别:
Modulation of T Cell Activation and Tolerance by DRAK2
DRAK2 对 T 细胞激活和耐受性的调节
  • 批准号:
    7379929
  • 财政年份:
    2005
  • 资助金额:
    $ 26.21万
  • 项目类别:

相似海外基金

Mechanisms of peroxisome proliferator-activated receptor-alpha regulation in peridontitis
过氧化物酶体增殖物激活受体-α在牙周炎中的调节机制
  • 批准号:
    10915090
  • 财政年份:
    2023
  • 资助金额:
    $ 26.21万
  • 项目类别:
Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 26.21万
  • 项目类别:
    Studentship
Regulation of cardiac small-conductance calcium-activated potassium channels by PIP2
PIP2 对心脏小电导钙激活钾通道的调节
  • 批准号:
    10751363
  • 财政年份:
    2023
  • 资助金额:
    $ 26.21万
  • 项目类别:
Titin-based stiffness regulation and mechanosensing in activated skeletal muscle.
激活骨骼肌中基于肌联蛋白的刚度调节和机械传感。
  • 批准号:
    10751746
  • 财政年份:
    2023
  • 资助金额:
    $ 26.21万
  • 项目类别:
Regulation of the early steps of wound-activated jasmonate biosynthesis
伤口激活茉莉酸生物合成早期步骤的调控
  • 批准号:
    2101975
  • 财政年份:
    2022
  • 资助金额:
    $ 26.21万
  • 项目类别:
    Standard Grant
Regulation of Mutationally Activated Gq/11
突变激活 Gq/11 的调控
  • 批准号:
    10551862
  • 财政年份:
    2021
  • 资助金额:
    $ 26.21万
  • 项目类别:
Regulation of Mutationally Activated Gq/11
突变激活 Gq/11 的调控
  • 批准号:
    10209429
  • 财政年份:
    2021
  • 资助金额:
    $ 26.21万
  • 项目类别:
Regulation of Mutationally Activated Gq/11
突变激活 Gq/11 的调控
  • 批准号:
    10376872
  • 财政年份:
    2021
  • 资助金额:
    $ 26.21万
  • 项目类别:
Regulation of mammalian brain development by p21-activated kinase signaling pathways
p21 激活激酶信号通路对哺乳动物大脑发育的调节
  • 批准号:
    RGPIN-2017-06295
  • 财政年份:
    2021
  • 资助金额:
    $ 26.21万
  • 项目类别:
    Discovery Grants Program - Individual
Regulation of tumor recurrence by stress activated neutrophils
应激激活中性粒细胞调节肿瘤复发
  • 批准号:
    10416030
  • 财政年份:
    2020
  • 资助金额:
    $ 26.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了